Analysis for clinical feature and outcome of chondroblastoma after surgical treatment: A single center experience of 92 cases

• Published in: Journal of orthopaedic science : official journal of the Japanese Orthopaedic Association Vol. 27; no. 1; pp. 235 - 241
• Main Authors: Wang, Jun, Du, Zhiye, Yang, Rongli, Tang, Xiaodong, Yan, Taiqiang, Guo, Wei
• Format: Journal Article
• Language: English
• Published: Japan Elsevier B.V 01.01.2022
• Subjects: Bone Neoplasms - diagnostic imaging; Bone Neoplasms - epidemiology; Bone Neoplasms - surgery; Chondroblastoma - diagnostic imaging; Chondroblastoma - epidemiology; Chondroblastoma - surgery; Humans; Neoplasm Recurrence, Local - epidemiology; Neoplasm Recurrence, Local - surgery; Patella; Retrospective Studies; Treatment Outcome
• ISSN: 0949-2658; 1436-2023
• DOI: 10.1016/j.jos.2020.12.009

Chondroblastoma is a rare, benign, cartilaginous bone tumor derived from epiphyseal chondrocytes. Although the clinical characteristics and experience of surgical treatment of the smaller number of patients has been reported in the literature, it is difficult to draw conclusions about the clinical and radiographic features and the outcome for surgical treatment of this disease due to the rarity of chondroblastoma. This study was aiming to review the epidemiologic characteristics and outcome of surgical management for patients with chondroblastoma. We performed a retrospective analysis of 92 patients with chondroblastoma. Clinical data, radiographic images, surgical treatment and outcome were analyzed. Eighty-two patients received the extensive intralesional curettage and ten cases had the En-block resection. The most common site of disease was proximal femur (20.7%, 19/92), followed by distal femur (18.5%, 17/92) and proximal tibia (16.3%, 15/92). The secondary aneurysmal bone cyst component was most common for chondroblastoma of the small irregular bones, such as patella and foot. Four (4.3%, 4/92) cases receiving the extensive intralesional curettage developed the local recurrence, respectively two at the proximal tibia, one at the pelvis and one at the calcaneus. Time to local recurrence were respectively 14.5, 8.8, 27.0 and 5.6 months, with the average 14 months. Kaplan–Meier estimated survivorship curve of local recurrence-free survival rates of one, two and five years were respectively 97.7%, 96.2% and 93.9%. The mean Musculoskeletal Tumor Society (MSTS) score was 29.4. At the last follow-up, no one had the pulmonary metastasis and death associated with the disease. Intralesional curettage plus local adjuvants can obtain satisfactory outcome for chondroblastoma. Level IV.